Utility of Low-Dose Duvelisib for Advanced Mycosis Fungoides: A Single-Institution Study
Oncologist. 2024 Jan 18:oyad345. doi: 10.1093/oncolo/oyad345. Online ahead of print.ABSTRACTDuvelisib, a small-molecule phosphatidylinositol 3-kinase-δ,γ inhibitor, has shown efficacy for mycosis fungoides (MF) at dosage ranges of 25-100 mg twice daily (BID), but with significant toxicity. We conducted a retrospective cohort study of patients with advanced MF treated with low-dose duvelisib (15 mg every other day to BID), in an effort to minimize toxicity. A total of 7 patients were included. The overall response rate on duvelisib was 71%, with the remaining patients maintaining stable disease. Mean modified Severity Wei...
Source: The Oncologist - January 20, 2024 Category: Cancer & Oncology Authors: Christopher Bazewicz Nicolena Verardi Oleg Akilov Source Type: research

Development of a tetrahydroindazolone-based HDAC6 inhibitor with in-vivo anti-arthritic activity
Bioorg Med Chem. 2024 Feb 1;99:117587. doi: 10.1016/j.bmc.2024.117587. Epub 2024 Jan 7.ABSTRACTHistone deacetylase 6 (HDAC6) induces the expression of pro-inflammatory cytokines in macrophages; therefore, HDAC inhibitors may be beneficial for the treatment of macrophage-associated immune disorders and chronic inflammatory diseases, including atherosclerosis and rheumatoid arthritis. Structure-activity relationship studies were conducted on various phenyl hydroxamate HDAC6 inhibitors with indolone/indazolone-based bi- or tricyclic ring moieties as the cap group aiming to develop novel anti-arthritic drug candidates. Several...
Source: Bioorganic and Medicinal Chemistry - January 18, 2024 Category: Chemistry Authors: Hyun-Mo Yang Changsik Lee Jaeki Min Nina Ha Daekwon Bae Gibeom Nam Hyun-Ju Park Source Type: research

Chemical exposures and demographic associations in cutaneous T-cell lymphoma: a large single institution physician validated cohort study
AbstractCutaneous T-cell lymphomas (CTCL) are a rare group of T-cell neoplasms which infiltrate the skin and can result in substantial morbidity and mortality. Risk factors for CTCL are still poorly understood though recent studies suggest chemical exposures may play a role in its development. To further characterize patient-centered risk factors for CTCL, especially compared with matched controls, we performed one of the largest prospective cohort survey studies to date to examine patient-reported exposures and health-related quality of life (HRQoL) in association with concurrent clinical disease characteristics. Patient ...
Source: Archives of Dermatological Research - January 18, 2024 Category: Dermatology Source Type: research

Computational Flow Cytometry Accurately Identifies Sezary Cells Based on Simplified Aberrancy and Clonality Features
Flow cytometric identification of circulating neoplastic cells (Sezary cells) in patients with mycosis fungoides (MF) and Sezary syndrome (SS) is essential for diagnosis, staging and prognosis. While recent advances have improved the performance of this laboratory assay, the complex immunophenotype of Sezary cells and overlap with reactive T cells demand a high level of analytic expertise. We utilized machine learning to simplify this analysis using only 2 pre-defined Sezary cell-gating plots. We studied 114 samples from 59 patients with SS/MF, and 66 samples from unique patients with inflammatory dermatoses. (Source: Jour...
Source: Journal of Investigative Dermatology - January 16, 2024 Category: Dermatology Authors: Jansen N. Seheult, Matthew J. Weybright, Dragan Jevremovic, Min Shi, Horatiu Olteanu, Pedro Horna Tags: Original Article Source Type: research

Allogeneic transplantation and cellular therapies in cutaneous T-cell lymphoma
Expert Rev Anticancer Ther. 2024 Jan-Feb;24(1-2):41-58. doi: 10.1080/14737140.2024.2305356. Epub 2024 Feb 12.ABSTRACTINTRODUCTION: Mycosis fungoides (MF) and Sezary syndrome (SS) are the most common types of cutaneous T-cell lymphoma. Although many available treatments offer temporary disease control, allogeneic hematopoietic stem cell transplant (allo-HSCT) is the only curative treatment option for advanced stage MF and SS. CAR T-cell therapy is a promising new avenue for treatment.AREAS COVERED: In this review, we discuss the evidence supporting the use of allo-HSCT for the treatment of MF/SS, including disease status at...
Source: Expert Review of Anticancer Therapy - January 15, 2024 Category: Cancer & Oncology Authors: Amrita Goyal Francine Foss Source Type: research

Unsupervised SoftOtsuNet Augmentation for Clinical Dermatology Image Classifiers
AMIA Annu Symp Proc. 2024 Jan 11;2023:329-338. eCollection 2023.ABSTRACTData Augmentation is a crucial tool in the Machine Learning (ML) toolbox because it can extract novel, useful training images from an existing dataset, thereby improving accuracy and reducing overfitting in a Deep Neural Network (DNNs). However, clinical dermatology images often contain irrelevant background information,such as furniture and objects in the frame. DNNs make use of that information when optimizing the loss function. Data augmentation methods that preserve this information risk creating biases in the DNN's understanding (for example, that...
Source: AMIA Annual Symposium Proceedings - January 15, 2024 Category: Bioinformatics Authors: Miguel Dominguez John T Finnell Source Type: research